Neogen Corp.

Neogen develops, manufactures, and markets a line of products for food and animal safety. The company's segments are: Food Safety, which is engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; and Animal Safety, which is engaged in the development, production and marketing of products dedicated to animal safety, including a range of consumable products marketed to veterinarians and animal health product distributors, and provides genomic identification and related interpretive bioinformatic services.
  • TickerNEOG
  • ISINUS6404911066
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States

An unfavourable environment weighs on NEOGEN, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of NEOGEN (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date March 9, 2021, the closing price was USD 81.68 and its target price was estimated at USD 67.96.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Financial Sector names are at or near bullish price and RS inflections. (ex. WFC, ABCB, SNV, STL, NFBK, FII, and COF) • Many Healthcare Sector names are showing leadership characteristics. (ZBH, CUTR, UHS, HCA, CHE, AMED, WST, and NEOG) • Many IT service related names remain bullish. (ex. FISV, EBOV, GPN, TSS, and EXLS)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Financial Sector names are at or near bullish price and RS inflections. (ex. WFC, ABCB, SNV, STL, NFBK, FII, and COF) • Many Healthcare Sector names are showing leadership characteristics. (ZBH, CUTR, UHS, HCA, CHE, AMED, WST, and NEOG) • Many IT service related names remain bullish. (ex. FISV, EBOV, GPN, TSS, and EXLS)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Consumer Discretionary retailers and restaurants continue to be leadership. Many are breaking to new price and RS highs. • Auto parts and Shoe retailers stand out as leadership. • Healthcare Equipment & Supplies stocks remains an area of leadership with the Healthcare Sector.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Two concerns we have previously highlighted on our march to new highs have been (1) improved RS from defensive Sectors/Groups and (2) weak foreign equity markets. Defensive posturing and lack of global participation has had a dampening effect on risk sentiment in recent months. While questions remain, short-term developments highlighted below are encouraging and improve our already constructive outlook. • On cue, outperformance last week and yesterday from cyclical pockets of the market led the S&P 500 to new all-time highs while defensive Sectors lagged. Additionally, weakness in the US do...

Weekly Update: ATR, JBT, LECO, MIDD, NEOG, THO

Estimates Raised: ATR Opportunity of the Week:  MIDD News: LECO, NEOG, THO Current Report: MIDD Coming Events: JBT

Weekly Update: GNTX, LANC, NEOG, NDSN, RPM, SMG, WAB

Estimates Raised and Earnings Reported: LANC Estimates Lowered and Earnings Reported: NDSN News: GNTX, NEOG, SMG, RPM, WAB

Weekly Update: AIT, ATR, CDW, GNTX, JBT, LECO, LKQ, MATW, MTD, NEOG, POL, SCL, SMG, SYNT, THO, WAB

GLR BUYOUT!: SYNT Estimates Raised and Earnings Reported: GNTX, JBT, LKQ, SCL, WAB Estimates Lowered and Earnings Reported: POL Earnings Reported: AIT, LECO, MTD Estimates Lowered: THO News: ATR, MTD, NEOG Coming Events: CDW, SMG

An unfavourable environment weighs on NEOGEN, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of NEOGEN (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date March 9, 2021, the closing price was USD 81.68 and its target price was estimated at USD 67.96.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch